Immunization Strategies for the Control of Histoplasmosis

Maxwell T. Roth, Daniel Zamith-Miranda, Joshua D. Nosanchuk

Research output: Contribution to journalReview article

Abstract

Abstract: Histoplasmosis is an infection caused by the dimorphic fungus Histoplasma capsulatum. Histoplasmosis is typically self-limited and presents asymptomatically in most people. Nevertheless, histoplasmosis can cause severe pulmonary disease and death. Histoplasmosis is increasingly found worldwide; however, it is best documented in the endemic region of the Mississippi river valley system in the Eastern part of the United States (US). Epidemiological studies from the US detailing the morbidity, mortality, and cost associated with histoplasmosis underscore the need to develop a vaccine. Purpose of Review: This review will detail some of the major developments in potential vaccines against histoplasmosis, with particular emphasis on those that could be used to immunize immunocompromised hosts. Additionally, this review will highlight some non-traditional vaccine-like ideas for the prevention of diverse mycoses. Recent Findings: Historically, immunization strategies against histoplasmosis have largely focused on identifying immunogenic proteins that confer protection in animal models. More recently, novel active, therapeutic, and immunomodulatory strategies have been explored as potential alternatives for those with various immune deficiencies. Summary: The studies summarized in this review demonstrate that more research is needed to clarify the immunobiology, clinical role, and efficacy of each candidate vaccine in the ever-expanding potential armamentarium against histoplasmosis.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalCurrent Tropical Medicine Reports
Volume6
Issue number2
DOIs
StatePublished - Jun 15 2019

Fingerprint

Histoplasmosis
Immunization
Vaccines
Histoplasma
Mississippi
Mycoses
Immunocompromised Host
Rivers
Lung Diseases
Epidemiologic Studies
Fungi
Animal Models
Morbidity
Costs and Cost Analysis
Mortality
Infection

Keywords

  • Antibodies
  • Histoplasma capsulatum
  • Histoplasmosis
  • Immune therapy
  • T cells
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Immunization Strategies for the Control of Histoplasmosis. / Roth, Maxwell T.; Zamith-Miranda, Daniel; Nosanchuk, Joshua D.

In: Current Tropical Medicine Reports, Vol. 6, No. 2, 15.06.2019, p. 35-41.

Research output: Contribution to journalReview article

Roth, Maxwell T. ; Zamith-Miranda, Daniel ; Nosanchuk, Joshua D. / Immunization Strategies for the Control of Histoplasmosis. In: Current Tropical Medicine Reports. 2019 ; Vol. 6, No. 2. pp. 35-41.
@article{cd615edf987b4a7790a114a5d4cec59e,
title = "Immunization Strategies for the Control of Histoplasmosis",
abstract = "Abstract: Histoplasmosis is an infection caused by the dimorphic fungus Histoplasma capsulatum. Histoplasmosis is typically self-limited and presents asymptomatically in most people. Nevertheless, histoplasmosis can cause severe pulmonary disease and death. Histoplasmosis is increasingly found worldwide; however, it is best documented in the endemic region of the Mississippi river valley system in the Eastern part of the United States (US). Epidemiological studies from the US detailing the morbidity, mortality, and cost associated with histoplasmosis underscore the need to develop a vaccine. Purpose of Review: This review will detail some of the major developments in potential vaccines against histoplasmosis, with particular emphasis on those that could be used to immunize immunocompromised hosts. Additionally, this review will highlight some non-traditional vaccine-like ideas for the prevention of diverse mycoses. Recent Findings: Historically, immunization strategies against histoplasmosis have largely focused on identifying immunogenic proteins that confer protection in animal models. More recently, novel active, therapeutic, and immunomodulatory strategies have been explored as potential alternatives for those with various immune deficiencies. Summary: The studies summarized in this review demonstrate that more research is needed to clarify the immunobiology, clinical role, and efficacy of each candidate vaccine in the ever-expanding potential armamentarium against histoplasmosis.",
keywords = "Antibodies, Histoplasma capsulatum, Histoplasmosis, Immune therapy, T cells, Vaccine",
author = "Roth, {Maxwell T.} and Daniel Zamith-Miranda and Nosanchuk, {Joshua D.}",
year = "2019",
month = "6",
day = "15",
doi = "10.1007/s40475-019-00172-3",
language = "English (US)",
volume = "6",
pages = "35--41",
journal = "Current Tropical Medicine Reports",
issn = "2196-3045",
publisher = "Springer International Publishing AG",
number = "2",

}

TY - JOUR

T1 - Immunization Strategies for the Control of Histoplasmosis

AU - Roth, Maxwell T.

AU - Zamith-Miranda, Daniel

AU - Nosanchuk, Joshua D.

PY - 2019/6/15

Y1 - 2019/6/15

N2 - Abstract: Histoplasmosis is an infection caused by the dimorphic fungus Histoplasma capsulatum. Histoplasmosis is typically self-limited and presents asymptomatically in most people. Nevertheless, histoplasmosis can cause severe pulmonary disease and death. Histoplasmosis is increasingly found worldwide; however, it is best documented in the endemic region of the Mississippi river valley system in the Eastern part of the United States (US). Epidemiological studies from the US detailing the morbidity, mortality, and cost associated with histoplasmosis underscore the need to develop a vaccine. Purpose of Review: This review will detail some of the major developments in potential vaccines against histoplasmosis, with particular emphasis on those that could be used to immunize immunocompromised hosts. Additionally, this review will highlight some non-traditional vaccine-like ideas for the prevention of diverse mycoses. Recent Findings: Historically, immunization strategies against histoplasmosis have largely focused on identifying immunogenic proteins that confer protection in animal models. More recently, novel active, therapeutic, and immunomodulatory strategies have been explored as potential alternatives for those with various immune deficiencies. Summary: The studies summarized in this review demonstrate that more research is needed to clarify the immunobiology, clinical role, and efficacy of each candidate vaccine in the ever-expanding potential armamentarium against histoplasmosis.

AB - Abstract: Histoplasmosis is an infection caused by the dimorphic fungus Histoplasma capsulatum. Histoplasmosis is typically self-limited and presents asymptomatically in most people. Nevertheless, histoplasmosis can cause severe pulmonary disease and death. Histoplasmosis is increasingly found worldwide; however, it is best documented in the endemic region of the Mississippi river valley system in the Eastern part of the United States (US). Epidemiological studies from the US detailing the morbidity, mortality, and cost associated with histoplasmosis underscore the need to develop a vaccine. Purpose of Review: This review will detail some of the major developments in potential vaccines against histoplasmosis, with particular emphasis on those that could be used to immunize immunocompromised hosts. Additionally, this review will highlight some non-traditional vaccine-like ideas for the prevention of diverse mycoses. Recent Findings: Historically, immunization strategies against histoplasmosis have largely focused on identifying immunogenic proteins that confer protection in animal models. More recently, novel active, therapeutic, and immunomodulatory strategies have been explored as potential alternatives for those with various immune deficiencies. Summary: The studies summarized in this review demonstrate that more research is needed to clarify the immunobiology, clinical role, and efficacy of each candidate vaccine in the ever-expanding potential armamentarium against histoplasmosis.

KW - Antibodies

KW - Histoplasma capsulatum

KW - Histoplasmosis

KW - Immune therapy

KW - T cells

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85071661492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071661492&partnerID=8YFLogxK

U2 - 10.1007/s40475-019-00172-3

DO - 10.1007/s40475-019-00172-3

M3 - Review article

AN - SCOPUS:85071661492

VL - 6

SP - 35

EP - 41

JO - Current Tropical Medicine Reports

JF - Current Tropical Medicine Reports

SN - 2196-3045

IS - 2

ER -